Active Not Recruiting PHASE2 INTERVENTIONAL 1-arm
NCT07471815
Camrelizumab Plus Risedronate and Chemotherapy for Triple-Negative Breast Cancer: An Exploratory Clinical Study on Mechanisms and Efficacy
Mechanisms and Efficacy of Camrelizumab Plus Risedronate and Chemotherapy in Triple-Negative Breast Cancer: An Exploratory Clinical Study
Sponsor: Harbin Medical University
Conditions
Breast Cancer Triple Negative Breast Cancer
Interventions
Camrelizumab + Risedronate Sodium + Chemotherapy
Updated 1 time since 2026 Last updated: Mar 10, 2026 Started: Mar 4, 2026 Primary completion: Mar 31, 2028 Completion: Mar 31, 2029
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
This PHASE2 trial investigates Breast Cancer Triple Negative Breast Cancer and is currently ongoing. Harbin Medical University leads this study, which shows 1 recorded version since 2026 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
1 version recorded Active Not Recruiting — PHASE2
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Harbin Medical University
Data source: Harbin Medical University
For direct contact, visit the study record on ClinicalTrials.gov .